Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in RCC – Tweetorial #2




Provided by Integrity Continuing Education, Inc.


This activity is supported by educational grants from Eisai, Inc. and Merck Sharp & Dohme Corp.


This activity will examine the synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced Renal Cell Carcinoma (RCC) and discuss the safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting


The standards of care for advanced renal cell carcinoma (aRCC) have been evolving at an ever-accelerating pace over the last 20 years. Improvements in the understanding of the immunogenic nature and pathogenic drivers of this disease uncovered synergistic mechanisms between immunotherapies and antiangiogenic treatments that were previously used in single-agent treatment strategies.

This led to the new “gold standard” of first-line treatment for aRCC, which is to combine immuno-oncology (IO) using the immune checkpoint inhibitors (ICIs) and antiangiogenic tyrosine kinase inhibitors (TKIs) that block vascular endothelial growth factor and its receptors. This combination strategy has extended progression-free survival and overall survival beyond what could previously be hoped for with TKI or ICI monotherapy.

Determining which patient should receive which combination has become a complex question with no clear consensus.   As additional combination strategies advance in clinical trials, the question gets ever-more complicated.

This program will increase your ability to assess the efficacy and safety data from new and emerging combinations and aid your treatment decision making process for these patients.


Moshe C. Ornstein, MD, MA
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Associate Staff, Genitourinary Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio


Sumanta K. Pal, MD, FASCO
Professor, Department of Medical Oncology
Co-Director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California


Brian I. Rini, MD, FASCO
Ingram Professor of Medicine
Vanderbilt University Medical Center
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee


Release date: December 13, 2021
Expiration date: December 13, 2022
Estimated time to complete activity: 15 minutes



This educational activity has been designed to meet the needs of oncologists, pathologists, histologists, nephrologists, urologists, nurse practitioners, physician’s assistants, nurses, pharmacists, fellows, and other professionals involved in the management of patients with RCC particularly in the community setting.


Upon completion of this educational activity, participants should be able to:

  • ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC
  • COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting
  • EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC

There are no fees for participating and receiving CME credit for this activity. During the period of December 13, 2021 to December 13, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Moshe C. Ornstein, MD, MA
Consulting Fees: Aveo, Bristol Myers Squibb, Calithera, Eisai, Exelixis, Merck, Pfizer
Fees for Non-CME/CE Services: Bristol Myers Squibb

Sumanta K. Pal, MD, FASCO has no real or apparent conflicts of interest to disclose.

Brian Rini, MD, FASCO
Consulting Fees: 3DMedicines, Alkermes, Aveo, Compugen, Corvus, Eisai, Shionogi, Synthorx
Research Funding (Institution): AstraZeneca, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Mirati Therapeutics, Seattle Genetics, Taris
Consulting Fees/Research Funding (Institution): Aravive, Arrowhead Pharmaceuticals, Bristol-Myers Squibb, Genentech-Roche, GlaxoSmithKline, Pfizer, Merck, Surface Oncology
Stock: PTC Therapeutics

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Continue to Pretest